Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL20817249 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL2719411 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL6155137 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL10390115 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL1650291 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL825430 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019924 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 | |
| Enalapril SCHEMBL9019927 | 0.99 | SMN1; SMN2 (0.98) | SMN1; SMN2ACELMNAABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380522-A1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | Visterra, Inc. (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017091683-A1 | ANTIBODY MOLECULES TO APRIL AND USES THEREOF | Visterra, Inc. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20150366813-A1 | LIQUID-FILLED IMMEDIATE RELEASE SOFT GELATIN CAPSULES | PATHEON SOFTGELS INC | 2015-12-24 | — | — | US | disclosed |
| WO-2015195990-A1 | LIQUID-FILLED IMMEDIATE RELEASE SOFT GELATIN CAPSULES | BANNER LIFE SCIENCES LLC (US) | 2015-12-23 | — | — | WO | disclosed |
| EP-2736489-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | Cellworks Research India Private Limited (IN) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013016718-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | CELLWORKS RESEARCH INDIA PRIVATE LIMITED (IN) | 2013-01-31 | — | — | WO | disclosed |
| US-20120101630-A1 | PHARMACEUTICAL PACKAGING AND METHOD FOR DELIVERY OF SAME | DAYA MEDICALS, INC. | 2012-04-26 | — | — | US | disclosed |
| EP-2434017-A2 | Identification of a micro-RNA that activates expression of beta-myosin heavy chain | Board of Regents of the University of Texas System (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120040902-A1 | METHOD OF TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE | UNEMORI ELAINE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040903-A1 | METHOD FOR TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE | CORTHERA, INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2011044377-A2 | CHELATOR-TARGETING LIGAND CONJUGATES FOR CARDIOVASCULAR IMAGING | CELL POINT, LLC (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110085969-A1 | CHELATOR-TARGETING LIGAND CONJUGATES FOR CARDIOVASCULAR IMAGING | CELL>POINT, LLC | 2011-04-14 | — | — | US | disclosed |
| EP-2102214-B1 | 4, 5, 6, 7-TETRAHYDRO-THIENO [3, 2-C] PYRIDINE DERIVATIVES AS H3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-7902184-B2 | Piperazinyl pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2288366-A2 | METHOD OF TREATING CHRONIC HEART FAILURE | Corthera, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-2288373-A2 | TREATING DYSPNEA ASSOCIATED WITH ACUTE HEART FAILURE WITH RELAXIN | Corthera, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1957479-B1 | 1,5-SUBSTITUTED INDOL-2-YL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011011114-A2 | PHARMACEUTICAL PACKAGING AND METHOD FOR DELIVERY OF SAME | DAYA MEDICALS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2002087503-A2 | COMPOSITIONS AND METHODS FOR TREATING COLORECTAL POLYPS AND CANCER | VANDERBILT UNIVERSITY (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002059343-A2 | BIOLOGICAL MARKERS AND DIAGNOSTIC TESTS FOR ANGIOTENSIN CONVERTING ENZYME INHIBITOR- AND VASOPEPTIDASE INHIBITOR-ASSOCIATED ANGIOEDEMA | VANDERBILT UNIVERSITY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110085969-A1 | CHELATOR-TARGETING LIGAND CONJUGATES FOR CARDIOVASCULAR IMAGING | SLC2A8, SLC2A1, SLC2A2 | ACE 1634/4885SMN1; SMN2 2522/4885LMNA 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.